3
项与 L-天冬酰胺酶(Chandra Bhagat Pharma Ltd.) 相关的临床试验Pethema LAL-RI/2008: Treatment for Patients With Standard Risk Acute
Understand the dynamics of elimination of MRD in adult patients with standard-risk LAL treated with a pediatric protocol.
LAL-AR-N-2005: Study Treatment for Children High Risk Acute Lymphoblastic Leukemia
The study objective is to improve the global results obtained with LAL-AR-93 study, reaching an event free survival between 60-70%.
Identify patients with bad prognosis, with minimal residual disease,who can benefit of allogenic bone marrow transplantation
LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive
Due to ALL Ph+ patients should receive a different treatment, is proposed a therapeutical protocol with: intensification treatment of induction to increment the CR rate, allogenic transplantation in first CR, autologous transplantation follow by alfa interferon in patients cannot done allogenic transplantation.
100 项与 L-天冬酰胺酶(Chandra Bhagat Pharma Ltd.) 相关的临床结果
100 项与 L-天冬酰胺酶(Chandra Bhagat Pharma Ltd.) 相关的转化医学
100 项与 L-天冬酰胺酶(Chandra Bhagat Pharma Ltd.) 相关的专利(医药)
1
项与 L-天冬酰胺酶(Chandra Bhagat Pharma Ltd.) 相关的文献(医药)Principal biochemical characteristics of the EC-2 L-asparaginase from Escherichia coli AT.
100 项与 L-天冬酰胺酶(Chandra Bhagat Pharma Ltd.) 相关的药物交易